Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_4
2
33%
Ph phase_1
2
33%
Ph not_applicable
1
17%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
2(33.3%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(5)
Other(1)

Detailed Status

Completed5
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (33.3%)
Phase 31 (16.7%)
Phase 42 (33.3%)
N/A1 (16.7%)

Trials by Status

completed583%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

NCT03976752
completedphase_4

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

NCT03693508
unknownphase_4

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

NCT03549312
completednot_applicable

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

NCT02251236
completedphase_1

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03976752Phase 1

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

Completed
NCT03693508Phase 4

A Clinical Trial to Evaluate the Efficacy and Safety of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide as a First-line Treatment in Naïve Patients With HIV-1 Infection With Severe Immunosuppression

Completed
NCT03549312Phase 4

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Unknown
NCT02251236Not Applicable

Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals

Completed
NCT02985996Phase 1

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

Completed
NCT02998320Phase 3

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6